{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T10:19:54Z","timestamp":1790763594485,"version":"4.1.0"},"reference-count":87,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","thebonejournal.com","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.bone.2016.10.019","type":"journal-article","created":{"date-parts":[[2016,10,24]],"date-time":"2016-10-24T15:33:07Z","timestamp":1477323187000},"page":"63-75","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":126,"special_numbering":"C","title":["Effects of sclerostin antibodies in animal models of osteoporosis"],"prefix":"10.1016","volume":"96","author":[{"given":"Michael Stuart","family":"Ominsky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rogely Waite","family":"Boyce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua Zhu","family":"Ke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.bone.2016.10.019_bb0005","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1001\/jama.285.6.785","article-title":"Osteoporosis prevention, diagnosis, and therapy","volume":"285","author":"NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy","year":"2001","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.bone.2016.10.019_bb0010","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1359\/JBMR.040710","article-title":"Bone remodeling increases substantially in the years after menopause and remains increased in older osteoporosis patients","volume":"19","author":"Recker","year":"2004","journal-title":"J. Bone Miner. Res."},{"issue":"Suppl. 4","key":"10.1016\/j.bone.2016.10.019_bb0015","first-page":"iv2","article-title":"Structural basis of growth-related gain and age-related loss of bone strength","volume":"47","author":"Seeman","year":"2008","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.bone.2016.10.019_bb0020","series-title":"Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism","first-page":"508","article-title":"Osteoporosis in Men","author":"Orwoll","year":"2013"},{"issue":"2","key":"10.1016\/j.bone.2016.10.019_bb0025","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nrendo.2011.146","article-title":"Antiresorptive therapies for osteoporosis: a clinical overview","volume":"8","author":"Chen","year":"2011","journal-title":"Nat. Rev. Endocrinol."},{"issue":"9","key":"10.1016\/j.bone.2016.10.019_bb0030","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/ncpendmet0941","article-title":"Selection of antiresorptive or anabolic treatments for postmenopausal osteoporosis","volume":"4","author":"Papapoulos","year":"2008","journal-title":"Nat. Clin. Pract. Endocrinol. Metab."},{"issue":"2","key":"10.1016\/j.bone.2016.10.019_bb0035","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/nrd3299","article-title":"Emerging therapeutic opportunities for skeletal restoration","volume":"10","author":"Kawai","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"issue":"13","key":"10.1016\/j.bone.2016.10.019_bb0040","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1096\/fj.05-4221fje","article-title":"Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation","volume":"19","author":"Poole","year":"2005","journal-title":"FASEB J."},{"issue":"22","key":"10.1016\/j.bone.2016.10.019_bb0045","doi-asserted-by":"crossref","first-page":"19489","DOI":"10.1074\/jbc.M110.190330","article-title":"Bone overgrowth-associated mutations in the LRP4 gene impair sclerostin facilitator function","volume":"286","author":"Leupin","year":"2011","journal-title":"J. Biol. Chem."},{"issue":"10","key":"10.1016\/j.bone.2016.10.019_bb0050","first-page":"401","article-title":"Sclerosteosis in old age","volume":"58","author":"Barnard","year":"1980","journal-title":"S. Afr. Med. J."},{"issue":"3","key":"10.1016\/j.bone.2016.10.019_bb0055","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1136\/jmg.25.3.200","article-title":"Sclerosteosis","volume":"25","author":"Beighton","year":"1988","journal-title":"J. Med. Genet."},{"issue":"3","key":"10.1016\/j.bone.2016.10.019_bb0060","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1034\/j.1399-0004.2003.00036.x","article-title":"The natural history of sclerosteosis","volume":"63","author":"Hamersma","year":"2003","journal-title":"Clin. Genet."},{"issue":"16","key":"10.1016\/j.bone.2016.10.019_bb0065","doi-asserted-by":"crossref","first-page":"10890","DOI":"10.1074\/jbc.M807994200","article-title":"Characterization of the structural features and interactions of sclerostin: molecular insight into a key regulator of Wnt-mediated bone formation","volume":"284","author":"Veverka","year":"2009","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.bone.2016.10.019_bb0070","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1359\/jbmr.081206","article-title":"Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis","volume":"24","author":"Li","year":"2009","journal-title":"J. Bone Miner. Res."},{"issue":"1","key":"10.1016\/j.bone.2016.10.019_bb0075","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/jbmr.173","article-title":"Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody","volume":"26","author":"Padhi","year":"2011","journal-title":"J. Bone Miner. Res."},{"issue":"5","key":"10.1016\/j.bone.2016.10.019_bb0080","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1056\/NEJMoa1305224","article-title":"Romosozumab in postmenopausal women with low bone mineral density","volume":"370","author":"McClung","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.bone.2016.10.019_bb0085","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1002\/jbmr.2092","article-title":"Single- and multiple-dose randomized studies of blosozumab, a monoclonal antibody against sclerostin, in healthy postmenopausal women","volume":"29","author":"McColm","year":"2014","journal-title":"J. Bone Miner. Res."},{"issue":"2","key":"10.1016\/j.bone.2016.10.019_bb0090","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/jbmr.2351","article-title":"A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density","volume":"30","author":"Recker","year":"2015","journal-title":"J. Bone Miner. Res."},{"issue":"Suppl. 1","key":"10.1016\/j.bone.2016.10.019_bb0095","article-title":"BPS804, an anti-sclerostin monoclonal antibody, improves disease biomarkers and markers of bone formation in patients with adult onset hypophosphatasia (HPP)","volume":"28","author":"Seefried","year":"2013","journal-title":"J. Bone Miner. Res."},{"issue":"5","key":"10.1016\/j.bone.2016.10.019_bb0100","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1210\/er.2011-1060","article-title":"Sclerostin and Dikkopf-1 as therapeutic targets in bone diseases","volume":"33","author":"Ke","year":"2012","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.bone.2016.10.019_bb0105","series-title":"Guideline on the Evaluation of Medicinal Products in the Treatment of Primary Osteoporosis","author":"European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP)","year":"2007"},{"issue":"8","key":"10.1016\/j.bone.2016.10.019_bb0110","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1002\/jbmr.2482","article-title":"Transcriptional profiling of laser capture microdissected subpopulations of the osteoblast lineage provides insight into the early response to sclerostin antibody in rats","volume":"30","author":"Nioi","year":"2015","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2016.10.019_bb0115","series-title":"Annual Meeting of American Society for Bone and Mineral Research","first-page":"16","article-title":"Sclerostin antibody administration converts bone lining cells into active osteoblasts","author":"Wein","year":"2016"},{"issue":"6","key":"10.1016\/j.bone.2016.10.019_bb0120","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1002\/jbmr.2152","article-title":"Tissue-level mechanisms responsible for the increase in bone formation and bone volume by sclerostin antibody","volume":"29","author":"Ominsky","year":"2014","journal-title":"J. Bone Miner. Res."},{"issue":"5","key":"10.1016\/j.bone.2016.10.019_bb0125","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1002\/jbmr.14","article-title":"Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength","volume":"25","author":"Ominsky","year":"2010","journal-title":"J. Bone Miner. Res."},{"issue":"12","key":"10.1016\/j.bone.2016.10.019_bb0130","doi-asserted-by":"crossref","first-page":"4785","DOI":"10.1210\/en.2013-1905","article-title":"Progressive increases in bone mass and bone strength in an ovariectomized rat model of osteoporosis after 26weeks of treatment with a sclerostin antibody","volume":"155","author":"Li","year":"2014","journal-title":"Endocrinology"},{"issue":"Suppl. 1","key":"10.1016\/j.bone.2016.10.019_bb0135","article-title":"Romosozumab (sclerostin antibody) increases wall thickness in remodeling units in cynomolgus monkeys after 28weeks","volume":"30","author":"Niu","year":"2015","journal-title":"J. Bone Miner. Res."},{"issue":"Suppl. 1","key":"10.1016\/j.bone.2016.10.019_bb0140","article-title":"Long-term sclerostin antibody treatment in cynomolgus monkeys: sustained in vertebral microarchitecture and bone strength following a temporal increase in cancellous bone formation","volume":"27","author":"Ominsky","year":"2012","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2016.10.019_bb0145","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.bone.2015.08.007","article-title":"Differential temporal effects of sclerostin antibody and parathyroid hormone on cancellous and cortical bone and quantitative differences in effects on the osteoblast lineage in young intact rats","volume":"81","author":"Ominsky","year":"2015","journal-title":"Bone"},{"key":"10.1016\/j.bone.2016.10.019_bb0150","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.bone.2015.12.013","article-title":"Time-dependent cellular and transcriptional changes in the osteoblast lineage associated with sclerostin antibody treatment in ovariectomized rats","volume":"84","author":"Taylor","year":"2016","journal-title":"Bone"},{"key":"10.1016\/j.bone.2016.10.019_bb0155","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.bone.2014.07.031","article-title":"Temporal changes in systemic and local expression of bone turnover markers during six months of sclerostin antibody administration to ovariectomized rats","volume":"67","author":"Stolina","year":"2014","journal-title":"Bone"},{"key":"10.1016\/j.bone.2016.10.019_bb0160","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms11505","article-title":"A bispecific antibody targeting sclerostin and DKK-1 promotes bone mass accrual and fracture repair","volume":"7","author":"Florio","year":"2016","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.bone.2016.10.019_bb0165","doi-asserted-by":"crossref","first-page":"E478","DOI":"10.1073\/pnas.1409857112","article-title":"Osteocytes mediate the anabolic actions of canonical Wnt\/\u03b2-catenin signaling in bone","volume":"112","author":"Tu","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"7","key":"10.1016\/j.bone.2016.10.019_bb0170","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1359\/JBMR.050210","article-title":"TOPGAL mice show that the canonical Wnt signaling pathway is active during bone development and growth and is activated by mechanical loading in vitro","volume":"20","author":"Hens","year":"2005","journal-title":"J. Bone Miner. Res."},{"issue":"Suppl. 1","key":"10.1016\/j.bone.2016.10.019_bb0175","article-title":"Romosozumab (sclerostin antibody) improves bone mass and bone strength in ovariectomized cynomolgus monkeys after 12months of treatment","volume":"30","author":"Ominsky","year":"2015","journal-title":"J. Bone Miner. Res."},{"issue":"5","key":"10.1016\/j.bone.2016.10.019_bb0180","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.devcel.2005.02.017","article-title":"Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation","volume":"8","author":"Glass","year":"2005","journal-title":"Dev. Cell"},{"issue":"5","key":"10.1016\/j.bone.2016.10.019_bb0185","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1002\/jbmr.307","article-title":"Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bones","volume":"26","author":"Ominsky","year":"2011","journal-title":"J. Bone Miner. Res."},{"issue":"Suppl. 1","key":"10.1016\/j.bone.2016.10.019_bb0190","article-title":"Treatment with sclerostin antibody converts trabecular rods into trabecular plates in male cynomolgus monkeys","volume":"30","author":"Matheny","year":"2015","journal-title":"J. Bone Miner. Res."},{"issue":"4","key":"10.1016\/j.bone.2016.10.019_bb0195","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.bone.2008.06.008","article-title":"Tissue modulus calculated from beam theory is biased by bone size and geometry: implications for the use of three-point bending tests to determine bone tissue modulus","volume":"43","author":"van Lenthe","year":"2008","journal-title":"Bone"},{"issue":"7","key":"10.1016\/j.bone.2016.10.019_bb0200","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1002\/jbmr.2188","article-title":"Bone matrix quality after sclerostin antibody treatment","volume":"29","author":"Ross","year":"2014","journal-title":"J. Bone Miner. Res."},{"issue":"9","key":"10.1016\/j.bone.2016.10.019_bb0205","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1210\/en.2011-0252","article-title":"Increased bone formation and bone mass induced by sclerostin antibody is not affected by pretreatment or cotreatment with alendronate in osteopenic, ovariectomized rats","volume":"152","author":"Li","year":"2011","journal-title":"Endocrinology"},{"issue":"Suppl. 1","key":"10.1016\/j.bone.2016.10.019_bb0210","article-title":"Infrequent co-treatment and sequential treatment of anti-sclerostin antibody with zoledronic acid restores and maintains bone mass in murine osteoporosis models","volume":"24","author":"Halleux","year":"2009","journal-title":"J. Bone Miner. Res."},{"issue":"Suppl. 1","key":"10.1016\/j.bone.2016.10.019_bb0215","article-title":"Bone anabolic effect of sclerostin antibody is maintained with antiresorptive agents in osteopenic, ovariectomized rats","volume":"28","author":"Ma","year":"2013","journal-title":"J. Bone Miner. Res."},{"issue":"Suppl. 1","key":"10.1016\/j.bone.2016.10.019_bb0220","article-title":"Retreatment with sclerostin antibody increased bone formation and bone mass in ovariectomized rats","volume":"28","author":"Li","year":"2013","journal-title":"J. Bone Miner. Res."},{"issue":"Suppl. 1","key":"10.1016\/j.bone.2016.10.019_bb0225","article-title":"Bone formation response in mice during administration and following re-challenge with an antibody to sclerostin","volume":"28","author":"Robinson","year":"2013","journal-title":"J. Bone Miner. Res."},{"issue":"9","key":"10.1016\/j.bone.2016.10.019_bb0230","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1002\/jbmr.2489","article-title":"The effect of discontinuing treatment with blosozumab: follow-up results of a phase 2 randomized clinical trial in postmenopausal women with low bone mineral density","volume":"30","author":"Recknor","year":"2015","journal-title":"J. Bone Miner. Res."},{"issue":"3","key":"10.1016\/j.bone.2016.10.019_bb0235","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1359\/jbmr.061113","article-title":"Incidence and economic burden of osteoporosis-related fractures in the United States, 2005\u20132025","volume":"22","author":"Burge","year":"2007","journal-title":"J. Bone Miner. Res."},{"issue":"12","key":"10.1016\/j.bone.2016.10.019_bb0240","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1002\/jbmr.182","article-title":"Q.T. Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats","volume":"25","author":"Li","year":"2010","journal-title":"J. Bone Miner. Res."},{"issue":"Suppl. 1","key":"10.1016\/j.bone.2016.10.019_bb0245","article-title":"Sclerostin inhibition by monoclonal antibody reversed trabecular and cortical bone loss in orchiectomized rats with established osteopenia","volume":"25","author":"Li","year":"2010","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2016.10.019_bb0250","doi-asserted-by":"crossref","first-page":"5866","DOI":"10.1074\/jbc.M705092200","article-title":"Mechanical stimulation of bone in vivo reduces osteocyte expression of sost\/sclerostin","volume":"283","author":"Robling","year":"2008","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.bone.2016.10.019_bb0255","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1007\/s00198-011-1656-4","article-title":"Mechanical loading-related changes in osteocyte sclerostin expression in mice are more closely associated with the subsequent osteogenic response than the peak strains engendered","volume":"23","author":"Moustafa","year":"2012","journal-title":"Osteoporos. Int."},{"issue":"10","key":"10.1016\/j.bone.2016.10.019_bb0260","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1359\/jbmr.090411","article-title":"Sclerostin mediates bone response to mechanical unloading through antagonizing Wnt\/beta-catenin signaling","volume":"24","author":"Lin","year":"2009","journal-title":"J. Bone Miner. Res."},{"issue":"2","key":"10.1016\/j.bone.2016.10.019_bb0265","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.bone.2010.09.009","article-title":"Sclerostin antibody increases bone mass by stimulating bone formation and inhibiting bone resorption in a hindlimb-immobilization rat model","volume":"48","author":"Tian","year":"2011","journal-title":"Bone"},{"issue":"211","key":"10.1016\/j.bone.2016.10.019_bb0270","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3006627","article-title":"Sclerostin inhibition reverses skeletal fragility in an Lrp5-deficient mouse model of OPPG syndrome","volume":"5","author":"Kedlaya","year":"2013","journal-title":"Sci. Transl. Med."},{"issue":"4","key":"10.1016\/j.bone.2016.10.019_bb0275","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1002\/jbmr.1807","article-title":"Bouxsein, sclerostin antibody inhibits skeletal deterioration due to reduced mechanical loading","volume":"28","author":"Spatz","year":"2013","journal-title":"J. Bone Miner. Res."},{"issue":"4","key":"10.1016\/j.bone.2016.10.019_bb0280","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1002\/jbmr.2396","article-title":"Sclerostin inhibition prevents spinal cord injury-induced cancellous bone loss","volume":"30","author":"Beggs","year":"2015","journal-title":"J. Bone Miner. Res."},{"issue":"11","key":"10.1016\/j.bone.2016.10.019_bb0285","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1002\/jbmr.2549","article-title":"Sclerostin antibody preserves the morphology and structure of osteocytes and blocks the severe skeletal deterioration after motor-complete spinal cord injury in rats","volume":"30","author":"Qin","year":"2015","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2016.10.019_bb0290","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.bone.2016.02.005","article-title":"Sclerostin antibody prevented progressive bone loss in combined ovariectomized and concurrent functional disuse","volume":"87","author":"Zhang","year":"2016","journal-title":"Bone"},{"issue":"Suppl. 1","key":"10.1016\/j.bone.2016.10.019_bb0295","article-title":"Sclerostin antibody treatment improves bone mass, microarchitecture and mechanical properties in mice exposed to microgravity: results from the STS-135 shuttle mission","volume":"27","author":"Bouxsein","year":"2012","journal-title":"J. Bone Miner. Res."},{"issue":"22","key":"10.1016\/j.bone.2016.10.019_bb0300","first-page":"19489","article-title":"Bone overgrowth-associated mutations in the LRP4 gene impair sclerostin facilitator function","volume":"286","author":"Lau","year":"2012","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.bone.2016.10.019_bb0305","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrd3669","article-title":"Inflammatory bone loss: pathogenesis and therapeutic intervention","volume":"11","author":"Redlich","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"issue":"10","key":"10.1016\/j.bone.2016.10.019_bb0310","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1359\/jbmr.090403","article-title":"A short treatment with an antibody to sclerostin can inhibit bone loss in an ongoing model of colitis","volume":"24","author":"Eddleston","year":"2009","journal-title":"J. Bone Miner. Res."},{"issue":"5","key":"10.1016\/j.bone.2016.10.019_bb0315","doi-asserted-by":"crossref","first-page":"R125","DOI":"10.1186\/ar4305","article-title":"Effect of sclerostin-neutralising antibody on periarticular and systemic bone in a murine model of rheumatoid arthritis: a microCT study","volume":"15","author":"Marenzana","year":"2013","journal-title":"Arthritis. Res. Ther."},{"issue":"8","key":"10.1016\/j.bone.2016.10.019_bb0320","article-title":"Sclerostin inhibition promotes TNF-dependent inflammatory joint destruction","volume":"330","author":"Wehmeyer","year":"2016","journal-title":"Sci. Transl. Med."},{"issue":"10","key":"10.1016\/j.bone.2016.10.019_bb0325","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1136\/annrheumdis-2013-203345","article-title":"Sclerostin inhibition reverses systemic, periarticular and local bone loss in arthritis","volume":"72","author":"Chen","year":"2013","journal-title":"Ann. Rheum. Dis."},{"issue":"6","key":"10.1016\/j.bone.2016.10.019_bb0330","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/nrendo.2016.59","article-title":"Does anti-sclerostin therapy promote inflammation in rheumatoid arthritis?","volume":"12","author":"Sims","year":"2016","journal-title":"Nat. Rev. Endocrinol."},{"issue":"6","key":"10.1016\/j.bone.2016.10.019_bb0335","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1359\/jbmr.2000.15.6.993","article-title":"Use of oral corticosteroids and risk of fractures","volume":"15","author":"Van Staa","year":"2000","journal-title":"J. Bone Miner. Res."},{"issue":"6","key":"10.1016\/j.bone.2016.10.019_bb0340","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1359\/JBMR.040134","article-title":"A meta-analysis of prior corticosteroid use and fracture risk","volume":"19","author":"Kanis","year":"2004","journal-title":"J. Bone Miner. Res."},{"issue":"8","key":"10.1016\/j.bone.2016.10.019_bb0345","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1002\/art.30385","article-title":"Sclerostin antibody treatment enhances bone strength but does not prevent growth retardation in young mice treated with dexamethasone","volume":"63","author":"Marenzana","year":"2011","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.bone.2016.10.019_bb0350","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.bone.2015.09.010","article-title":"Sclerostin antibody and interval treadmill training effects in a rodent model of glucocorticoid-induced osteopenia","volume":"81","author":"Achiou","year":"2015","journal-title":"Bone"},{"issue":"6","key":"10.1016\/j.bone.2016.10.019_bb0355","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1210\/en.2009-1488","article-title":"Intermittent parathyroid hormone administration counteracts the adverse effects of glucocorticoids on osteoblast and osteocyte viability, bone formation, and strength in mice","volume":"151","author":"Weinstein","year":"2010","journal-title":"Endocrinology"},{"issue":"1","key":"10.1016\/j.bone.2016.10.019_bb0360","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s00198-015-3308-6","article-title":"Sclerostin-antibody treatment of glucocorticoid-induced osteoporosis maintained bone mass and strength","volume":"27","author":"Yao","year":"2016","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2016.10.019_bb0365","doi-asserted-by":"crossref","DOI":"10.1002\/jbmr.2869","article-title":"Protection from glucocorticoid-induced osteoporosis by anti-catabolic signaling in the absence of sost\/sclerostin","author":"Sato","year":"2016","journal-title":"J. Bone Miner. Res."},{"issue":"3","key":"10.1016\/j.bone.2016.10.019_bb0370","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/jbmr.2372","article-title":"Anti-sclerostin antibody treatment in a rat model of progressive renal osteodystrophy","volume":"30","author":"Moe","year":"2015","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2016.10.019_bb0375","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.bone.2015.04.021","article-title":"Compromised vertebral structural and mechanical properties associated with progressive kidney disease and the effects of traditional pharmacological interventions","volume":"77","author":"Newman","year":"2015","journal-title":"Bone"},{"issue":"7","key":"10.1016\/j.bone.2016.10.019_bb0380","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.2337\/diacare.24.7.1192","article-title":"Type 1 and type 2 diabetes and incident hip fractures in postmenopausal women","volume":"24","author":"Kristin","year":"2001","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.bone.2016.10.019_bb0385","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1002\/jbmr.1803","article-title":"Sclerostin antibody treatment improves bone mass, bone strength, and bone defect regeneration in rats with type 2 diabetes mellitus","volume":"28","author":"Hamann","year":"2013","journal-title":"J. Bone Miner. Res."},{"issue":"11","key":"10.1016\/j.bone.2016.10.019_bb0390","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1002\/jbmr.1984","article-title":"Sclerostin antibody stimulates bone regeneration after experimental periodontitis","volume":"28","author":"Taut","year":"2013","journal-title":"J. Bone Miner. Res."},{"issue":"7","key":"10.1016\/j.bone.2016.10.019_bb0395","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1096\/fj.14-265496","article-title":"Removal of SOST or blocking its product sclerostin rescues defects in the periodontitis mouse models","volume":"29","author":"Ren","year":"2015","journal-title":"FASEB J."},{"key":"10.1016\/j.bone.2016.10.019_bb0400","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.matbio.2015.12.009","article-title":"Sclerostin antibody (Scl-Ab) improves osteomalacia phenotype in dentin matrix protein 1 (DMP1) knockout mice with little impact on serum levels of phosphorus and FGF23","volume":"52\u201354","author":"Ren","year":"2016","journal-title":"Matrix Biol."},{"issue":"6","key":"10.1016\/j.bone.2016.10.019_bb0405","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1002\/jbmr.2789","article-title":"Regulation of sclerostin expression in multiple myeloma by DKK-1: a potential therapeutic strategy for myeloma bone disease","volume":"31","author":"Eda","year":"2016","journal-title":"J. Bone Miner. Res."},{"issue":"5","key":"10.1016\/j.bone.2016.10.019_bb0410","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1158\/0008-5472.CAN-15-1703","article-title":"Bidirectional notch signaling and osteocyte-derived factors in the bone marrow microenvironment promote tumor cell proliferation and bone destruction in multiple myeloma","volume":"75","author":"Delgado-Calle","year":"2016","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.bone.2016.10.019_bb0415","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1002\/ijc.27342","article-title":"Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: reduction post-bortezomib monotherapy","volume":"131","author":"Terpos","year":"2012","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bone.2016.10.019_bb0420","series-title":"Annual European Calcified Tissue Society Congress","first-page":"14","article-title":"Anti-sclerostin treatment prevents multiple myeloma bone disease and reduces tumour burden","author":"McDonald","year":"2016"},{"key":"10.1016\/j.bone.2016.10.019_bb0425","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","author":"Cosman","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.bone.2016.10.019_bb0430","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0025900","article-title":"Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway","volume":"6","author":"Wijenayaka","year":"2011","journal-title":"PLoS One"},{"issue":"23","key":"10.1016\/j.bone.2016.10.019_bb0435","doi-asserted-by":"crossref","first-page":"6267","DOI":"10.1093\/emboj\/cdg599","article-title":"Osteocyte control of bone formation via sclerostin, a novel BMP antagonist","volume":"22","author":"Winkler","year":"2003","journal-title":"EMBO J."}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328216303155?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328216303155?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,14]],"date-time":"2019-09-14T20:04:03Z","timestamp":1568491443000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328216303155"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":87,"alternative-id":["S8756328216303155"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2016.10.019","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of sclerostin antibodies in animal models of osteoporosis","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2016.10.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}